Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, hairy cell
Stage/Subtype:  refractory hairy cell leukemia
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 57 for your search:
Start Over
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 130106, NCI-2015-01075, 13-C-0106, CD-ON-CAT-8015-1053, NCI-2013-00850, NCT01829711
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Dasatinib in Treating Patients with Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated with Autologous Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA-180-381, NCI-2012-00767, 1203010693, 2011-203, NCT01609816
Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-180-384, NCI-2012-00773, 2011-204, NCT01643603
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Brentuximab Vedotin and Rituximab in Treating Patients with Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
Laboratory Treated T Cells in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2639.00, NCI-2013-00073, 2639, NCT01865617
LMB-2 Immunotoxin in Treating Patients with Hairy Cell Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 06-C-0150, NCI-2009-00231, CDR0000482415, NCT00337311, P6760, 7834, NCI-06-C-0150, NCI-P6760, NCI-7834, NCT00321555
Cladribine and Rituximab in Treating Patients with Hairy Cell Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2004-0223, NCI-2012-01394, NCT00412594
Cladribine with Simultaneous or Delayed Rituximab in Treating Patients with Hairy Cell Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-C-0005, NCI-2013-01595, NCT00781235, P08372, NCT00923013
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, 2212, NCT00968630
Rituximab and Pentostatin or Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hairy Cell Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0025, NCI-2013-01455, P09576, NCT01059786
Rasburicase or Allopurinol in Preventing Tumor Lysis Syndrome in Patients with Hematological Malignancies Undergoing Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2010-0284, NCI-2012-01889, NCI-2010-02082, NCT01200485
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11D.247, NCI-2011-02345, 1795, 2011-31, NCT01384513
Fludarabine Phosphate, Melphalan, and Total-Body Irradiation before Donor Double Umbilical Cord Blood Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 11-085, NCI-2012-00147, NCT01408563
Bulk or Fractionated Stem Cell Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 12-016, NCI-2012-00824, NCT01596257
Vemurafenib in Treating Patients with Relapsed or Refractory Hairy Cell Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-200, NCI-2012-02170, NCT01711632
Donor T-cells after Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 14 to 75
Trial IDs: 12-1191, NCI-2013-00782, IRB12-1191-CR002, NCT01839916
Ibrutinib in Treating Patients with Relapsed Hairy Cell Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-12200, NCI-2013-00826, 9268, NCT01981512, 14-C-0004, NCT01841723
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Start Over